Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2019 May 10;375:32–45. doi: 10.1016/j.taap.2019.05.009

Figure 5.

Figure 5

Gadolinium-based contrast agents are metabolic disruptors. Mice were treated with gadolinium-based contrast agent, 2.5 mmol/kg intraperitoneally, 20 doses over 4 weeks. Metabolites from flash-frozen renal cortex from control and gadolinium-based contrast agent-treated (Gd) animals (n = 9 each) were quantified. A. Glycolytic pathway. B. Tricarboxylic acid (TCA) pathway. C. Mitochondrial oxidative phosphorylation (OXPHOS) metabolites. * P < 0.05, ** P < 0.01, *** P < 0.001 by t-test.